We are supporting trials in lymphoma that will deliver improvements to people living with this blood cancer.
A trial in Burkitt's lymphoma is comparing the standard chemotherapy with a new chemotherapy schedule, which could have less side effects, and it can be given in an outpatient setting with hospital visits rather than an hospital stay.
Our diffuse large B-cell lymphoma trials are looking for new ways to treat people who have not responded to the standard treatment of chemotherapy and antibody therapy.
Two peripheral T-cell lymphoma (PTCL) trials are testing new treatments for peopl who have not responded to chemotherapy, or who have relapsed after treatment.
We also have a Hodgkin lymphoma trial that wants to individually tailor treatment for each child, effectively treating the disease, but avoiding over-treatment and thereby reducing the late side-effects. And we have a trial which is looking a targeted biological therapy called brentuximab vedotin in adults with Hodgkin lymphoma who are unable to have standard chemotherapy.
And we have trials that want to improve the outcome for people with rarer lymphomas, such as peripheral central nervous system (PCNS) lymphoma, and post-transplant lymphoproliferative disorders (PTLD).